Aurobindo Pharma (AUROPHARMA) – Full Analysis
Technical View
As seen in the daily chart, the stock showed high volatility today.
Opened at ₹1070, made a high of ₹1071, low of ₹1040.20, and closed at ₹1046.40.
The stock is facing resistance near the 14-day EMA and failed to close above ₹1080, indicating no short-term buy signal yet.
On the weekly chart, the stock is holding support near the 200-day EMA and the crucial ₹995 zone.
In the long term, any dip towards the ₹1000–1020 zone could provide a buy-on-dips opportunity.
Upside potential: Over the next 6–8 months, the stock may retest the ₹1250–1300 levels if support sustains
Fundamental View
Business Model: AUROPHARMA is among India’s top pharmaceutical companies with a strong presence in generic drugs, formulations, and APIs across regulated markets (US, EU).
Financials:
Revenue growth supported by US formulations and API exports.
Margins under pressure due to pricing challenges in US generics and higher R&D expenses.
Debt levels reducing gradually, improving balance sheet strength.
Valuation: Currently trading below its historical P/E average, making it attractive for long-term investors.
Micro Factors (Company-specific)
Strong USFDA-approved manufacturing base.
Expansion in injectables and biosimilars.
Cost optimization initiatives in place.
Near-term margin pressure due to raw material cost and pricing erosion.
Macro Factors (Industry & Economy)
Pharma sector benefiting from global demand for affordable generics.
INR depreciation supports exporters like AUROPHARMA.
Regulatory risk (USFDA audits, compliance) remains a key overhang.
Healthcare spending in emerging markets is increasing, aiding growth.
Upcoming Events & Impact
Q2 FY26 Results (November 2025) → Expected to reflect better US business traction. Positive results could trigger momentum.
Product Launches in US/Europe → Likely to enhance revenue visibility.
USFDA Inspection Outcomes → Any adverse report may negatively impact the stock in short term.
Global Drug Pricing Trends → A major determinant of profitability.
Disclaimer
This analysis is for educational & informational purposes only and should not be considered as investment advice.
Disclosure
We, at Investogainer Research, SEBI Registered Research Analyst (INH000012856) & BSE Listed (Code: 5845), do not hold any personal/family interest or position in Aurobindo Pharma at the time of publishing this analysis.
For More Info:
Visit Us- www.investogainerresearch.com
Call Us- 9009099805, 9098804206
Email Us- info@investogainerresearch.com Daily Analysis on AUROPHARMA on 20082025